Answers are grounded in this paper and cite their sources.
Pheochromocytomas and pituitary adenomas in three patients with MAX exon deletions Dear Editor,Understanding of the genetic pathophysiology of endocrine tumors has advanced significantly and mutations in many causative genes are routinely sought.New syndromic associations among endocrine tumors have also been identified.These novel associations are important to recognize in order to direct screening appropriately.For instance, pheochromocytomas and pituitary adenomas can rarely occur together, usually due to germline SDHx mutations (Dénes et al. 2015, Xekouki et al. 2015, Guerrero Pérez et al. 2016).Despite a multitude of known genetic risk factors, many unexplained cases of multiple endocrine tumors exist (O'Toole et al. 2015).New causative genes and other genomic mechanisms affecting previously identified genes need to be considered during diagnostic workup.Copy number variations (CNV) are an important mechanism in inherited tumor genetics.CNV can affect large genetic regions or can be limited to deletions of single exons.Such exon-level intragenic deletions have been reported in connection with genes associated with isolated and syndromic endocrine neoplasia (Bayley et al. 2009, Ricketts et al. 2010, Zatelli et al. 2014).Identification of single exon deletions can be challenging.Techniques like multiplex ligation-dependent probe amplification (MLPA) and quantitative PCR are generally available and can identify CNV (e.g.deletions) of individual exons in cases where sequencing results are apparently normal.Mutations in the MAX gene are associated with a risk of sporadic and hereditary pheochromocytoma and are also implicated in kidney tumors (Comino-Méndez et al. 2011, Burnichon et al. 2012).Recently a large deletion including the MAX promoter and exons 1 and 2 was identified in a family with bilateral pheochromocytoma and renal oncocytoma (Korpershoek et al. 2016).Using MLPA we studied six sporadic cases with multiple endocrine tumors that were negative on NGS panels and Sanger sequencing for known risk genes.Patients provided their consent and the study was approved by the Ethics Committee Downloaded from Bioscientifica.
No takes yet. Share an insight, caveat, or question.
Daly et al. (2018) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: